Selventa CEO joins Swiss Institute of Bioinformatics
This article was originally published in Scrip
David de Graaf, president and CEO of Selventa, a personalised healthcare company focused on developing personalised biomarker panels, has been appointed to the scientific advisory board of the Swiss Institute of Bioinformatics, along with Professor Alexey Nesvizhskii from the University of Michigan. The SIB is an academic, non-profit foundation established in 1988 to co-ordinate research and education in bioinformatics throughout Switzerland.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.